Literature DB >> 35693396

Hepatocellular carcinoma as the Rose of Jericho: from the desert of sorafenib, to the blossoming of immunotherapy.

Antonio D'Alessio1,2, Lorenza Rimassa2,3.   

Abstract

Entities:  

Year:  2022        PMID： 35693396      PMCID： PMC9186197          DOI： 10.21037/hbsn-22-123

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   8.265


× No keyword cloud information.
  15 in total

1.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

Authors:  Richard S Finn; Shukui Qin; Masafumi Ikeda; Peter R Galle; Michel Ducreux; Tae-You Kim; Masatoshi Kudo; Valeriy Breder; Philippe Merle; Ahmed O Kaseb; Daneng Li; Wendy Verret; Derek-Zhen Xu; Sairy Hernandez; Juan Liu; Chen Huang; Sohail Mulla; Yulei Wang; Ho Yeong Lim; Andrew X Zhu; Ann-Lii Cheng
Journal:  N Engl J Med       Date:  2020-05-14       Impact factor: 91.245

2.  Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial.

Authors:  Vincenzo Mazzaferro; Davide Citterio; Sherrie Bhoori; Marco Bongini; Rosalba Miceli; Luciano De Carlis; Michele Colledan; Mauro Salizzoni; Renato Romagnoli; Barbara Antonelli; Marco Vivarelli; Giuseppe Tisone; Massimo Rossi; Salvatore Gruttadauria; Stefano Di Sandro; Riccardo De Carlis; Maria Grazia Lucà; Massimo De Giorgio; Stefano Mirabella; Luca Belli; Stefano Fagiuoli; Silvia Martini; Massimo Iavarone; Gianluca Svegliati Baroni; Mario Angelico; Stefano Ginanni Corradini; Riccardo Volpes; Luigi Mariani; Enrico Regalia; Maria Flores; Michele Droz Dit Busset; Carlo Sposito
Journal:  Lancet Oncol       Date:  2020-07       Impact factor: 41.316

Review 3.  Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma.

Authors:  Ambreen Muhammed; Antonio D'Alessio; Andrei Enica; Thomas Talbot; Claudia Angela Maria Fulgenzi; Georgios Nteliopoulos; Robert D Goldin; Alessio Cortellini; David J Pinato
Journal:  Expert Rev Mol Diagn       Date:  2022-03-18       Impact factor: 5.225

4.  Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.

Authors:  Ann-Lii Cheng; Shukui Qin; Masafumi Ikeda; Peter R Galle; Michel Ducreux; Tae-You Kim; Ho Yeong Lim; Masatoshi Kudo; Valeriy Breder; Philippe Merle; Ahmed O Kaseb; Daneng Li; Wendy Verret; Ning Ma; Alan Nicholas; Yifan Wang; Lindong Li; Andrew X Zhu; Richard S Finn
Journal:  J Hepatol       Date:  2021-12-11       Impact factor: 25.083

5.  Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study.

Authors:  Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Naoshi Nishida; Martin Schönlein; Johann von Felden; Kornelius Schulze; Henning Wege; Vincent E Gaillard; Anwaar Saeed; Brooke Wietharn; Hannah Hildebrand; Linda Wu; Celina Ang; Thomas U Marron; Arndt Weinmann; Peter R Galle; Dominik Bettinger; Bertram Bengsch; Arndt Vogel; Lorenz Balcar; Bernhard Scheiner; Pei-Chang Lee; Yi-Hsiang Huang; Suneetha Amara; Mahvish Muzaffar; Abdul Rafeh Naqash; Antonella Cammarota; Nicola Personeni; Tiziana Pressiani; Rohini Sharma; Matthias Pinter; Alessio Cortellini; Masatoshi Kudo; Lorenza Rimassa; David J Pinato
Journal:  Hepatology       Date:  2022-04-08       Impact factor: 17.298

6.  Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.

Authors:  Thomas U Marron; Maria Isabel Fiel; Pauline Hamon; Nathalie Fiaschi; Edward Kim; Stephen C Ward; Zhen Zhao; Joel Kim; Paul Kennedy; Ganesh Gunasekaran; Parissa Tabrizian; Deborah Doroshow; Meredith Legg; Ashley Hammad; Assaf Magen; Alice O Kamphorst; Muhammed Shareef; Namita T Gupta; Raquel Deering; Wei Wang; Fang Wang; Pradeep Thanigaimani; Jayakumar Mani; Leanna Troncoso; Alexandra Tabachnikova; Christie Chang; Guray Akturk; Mark Buckup; Steven Hamel; Giorgio Ioannou; Clotilde Hennequin; Hajra Jamal; Haley Brown; Antoinette Bonaccorso; Daniel Labow; Umut Sarpel; Talia Rosenbloom; Max W Sung; Baijun Kou; Siyu Li; Vladimir Jankovic; Nicola James; Sara C Hamon; Hung Kam Cheung; Jennifer S Sims; Elizabeth Miller; Nina Bhardwaj; Gavin Thurston; Israel Lowy; Sacha Gnjatic; Bachir Taouli; Myron E Schwartz; Miriam Merad
Journal:  Lancet Gastroenterol Hepatol       Date:  2022-01-20

7.  Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.

Authors:  Ahmed Omar Kaseb; Elshad Hasanov; Hop Sanderson Tran Cao; Lianchun Xiao; Jean-Nicolas Vauthey; Sunyoung S Lee; Betul Gok Yavuz; Yehia I Mohamed; Aliya Qayyum; Sonali Jindal; Fei Duan; Sreyashi Basu; Shalini S Yadav; Courtney Nicholas; Jing Jing Sun; Kanwal Pratap Singh Raghav; Asif Rashid; Kristen Carter; Yun Shin Chun; Ching-Wei David Tzeng; Divya Sakamuri; Li Xu; Ryan Sun; Vittorio Cristini; Laura Beretta; James C Yao; Robert A Wolff; James Patrick Allison; Padmanee Sharma
Journal:  Lancet Gastroenterol Hepatol       Date:  2022-01-20

Review 8.  Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?

Authors:  Ti Zhang; Philippe Merle; Huaqi Wang; Haitao Zhao; Masatoshi Kudo
Journal:  Hepatobiliary Surg Nutr       Date:  2021-04       Impact factor: 8.265

9.  PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.

Authors:  David J Pinato; Alessio Cortellini; Ajithkumar Sukumaran; Tom Cole; Madhava Pai; Nagy Habib; Duncan Spalding; Mikael H Sodergren; Maria Martinez; Tony Dhillon; Paul Tait; Robert Thomas; Caroline Ward; Hemant Kocher; Vincent Yip; Sarah Slater; Rohini Sharma
Journal:  BMC Cancer       Date:  2021-03-23       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.